A Peek Into The Market Before The Trading Starts

Pre-open movers US stock futures are lower this morning, as debt fears moved to Italy. Futures on the Dow Jones Industrial Average dropped 96 points to 12,393.00 and futures on the S&P 500 stock index fell 14.20 points to 2,344.75. Nasdaq 100 futures declined 22.25 points to 2,344.75. A Peek Into Global Markets Asian markets ended lower, with Japan's Nikkei Stock Average dropping 1.4262%, Australia's S&P/ASX 200 moving down 1.79% and China's Shanghai Composite declining 1.72%. Hong Kong's Hang Seng Index dipped 3.0611% and India's Sensex dipped 1.82%. European markets were lower today. The STOXX Europe 600 Index has dropped 1.95%, London's FTSE 100 Index moved down 1.51%, German DAX 30 index fell 2.24% and France CAC 40 index dipped 2.34%. Broker Recommendation Analysts at Jefferies & Company downgraded Procter & Gamble Co PG from “buy” to “hold.” The target price for Procter & Gamble has been lowered from $75.50 to $71. Procter & Gamble shares gained 0.12% to $64.80 in after-hours trading. Breaking news

• Cisco Systems, Inc. CSCO, the leader in networking equipment, is considering cuts to its workforce that could number as many as 10,000 people, two people familiar with the matter told Bloomberg. To read the full news, click here.
• A European court ruled Tuesday that internet auction website eBay EBAY may be liable for trademark infringement committed by its users. To read the full news, click here.
• The leaders of Central Vermont Public Service Corporation CV and Gaz Métro Limited Partnership today announced that a definitive agreement for the sale of CVPS has been signed. To read the full news, click here.
• Aeterna Zentaris Inc. AEZS today announced that the European Patent Office has granted a patent for the use of alkyl phosphocholines, more specifically perifosine (octadecyl 1,1-dimethylpiperidino-4-yl phosphate), in the preparation of a medicament for the treatment of benign and malignant tumours, prior to and/or during the treatment with approved anti-tumour anti-metabolites such as 5FU and capecitabine. To read the full news, click here.